Dataset Information

Acquisition of luteolytic capacity is accompanied by changes in luteal apoptosis and immune mechanisms

ABSTRACT: The corpus luteum (CL) produces progesterone to support pregnancy but undergoes luteolysis in response to prostaglandin F2A (PGF2A) when pregnancy is absent. Developing CL resist PGF2A-induced regression. This acquisition of luteolytic capacity (ALC) occurs around day 5 of the estrous cycle in cattle. To understand the mechanisms underlying ALC, we evaluated transcriptomic and proteomic changes in the CL on days 4 and 6 of the estrous cycle. 1190 transcripts were greater on day 4 and 119 were greater on day 6 (Padj < 0.05, log2FC > |1|). In the proteomics dataset, 2 proteins were greater on day 4, with 12 greater on day 6 (Padj < 0.05, log2FC > |1|). Data were integrated with datasets of luteal changes during luteolysis and during early pregnancy, and gene ontology analysis was used to identify candidate pathways regulating luteal PGF2A responsiveness, including apoptosis, cellular stress response, and cytokine signaling. Apoptosis regulators increased on day 6 and increased in response to PGF2A in vivo, indicating a likely role in luteolytic cell death. Changes to regulators of antigen presentation and T cell programming suggested increased T cell activation on day 6. A luteal cell culture experiment revealed that apoptosis pathways were regulated by interferon gamma and immune pathways were regulated by luteinizing hormone in vitro. In summary, integration across datasets from multiple luteal states allowed identification of proposed mediators governing luteal survival and PGF2A response. Apoptosis and immune-related pathways, changes indicating increased activated T cells, may poise the CL to regress in response to PGF2A.

ORGANISM(S): Bos taurus

PROVIDER: GSE307439 | GEO | 2026/03/16

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:In monoovulatory species like bovines, a striking diversity in regulation of the corpus luteum (CL) function exists within species during different stages of the luteal phase. The function and life span of CL appears to be regulated by the interplay of both luteotrophic and luteolytic factors, whose roles and actions are varied from one species to another. Although, studies continue to expand our current understanding of the cellular and molecular actions of prostaglandin F 2alpha (PGF2M-NM-1 - a physiological luteolysin)-induced luteolysis, knowledge of the mechanism whereby, PGF2M-NM-1 mediates its luteolytic actions remains poorly understood. The mechanism of PGF2M-NM-1-induced luteolysis is a complex process involving changes in expression of multiple genes encoding gene products that regulate steroidogenesis, stress related or apoptotic genes, factors involved in immune response and enzymes that stimulate PGF2M-NM-1 production. Thus, in the present study, efforts were made to identify the temporal changes in the global gene expression profile in the CL of buffalo cows in response to PGF2M-NM-1 treatment. The molecular signature of genome-wide transcriptional changes in the CL tissue subjected to PGF2M-NM-1-induced luteolysis will expand our knowledge on basic mechanism/s that regulates the luteolytic process. The results obtained in this study provide insight into the mechanisms underlying the PGF2M-NM-1- induced regression of CL.Keywords: CL, PGF2M-NM-1, gene expression The objective of this study was to identify the PGF2M-NM-1-induced temporal changes in transcriptome of bovine CL on day 11 of estrous cycle. In the experiments with buffalo cows, animals with history of normal estrous cyclicity were treated with Cloprostenol (an PGF2M-NM-1 analogue; 500 M-BM-5g i.m.) on day 11 of the estrous cycle to induce luteolysis and CL tissues were collected at (control; n=4 amimals/time point), 3 (n=2 animals/time point), 6 and 18 (n=3 animals/time point) h post PGF2M-NM-1 administration to examine gene expression changes associated with immediate early and delayed changes in the CL, respectively. Following retrieval of CL from the ovary, flash frozen in liquid nitrogen and stored at -70 M-BM-0C for the purpose of RNA isolation. The isolated RNA was labeled and hybridized to Affymetrix GeneChip Bovine Genome Arrays as per the manufacturerM-bM-^@M-^Ys instructions.

Project description:To explore chorionic gonadotropin (CG)-regulated gene expression in the primate corpus luteum (CL), adult female rhesus macaques were treated with a model of simulated early pregnancy (SEP). Total RNA was isolated from individual CL and hybridized to AffymetrixM-bM-^DM-" GeneChip Rhesus Macaque Genome Arrays The level of 1192 transcripts changed expression > 2-fold (one-way ANOVA, FDR correction; P<0.05) during SEP when compared to Day 10 untreated controls, and the majority of changes occurred between Days 10 and 12 of SEP. To compare transcript levels between SEP rescued and regressing CL, previously banked rhesus GeneChip array data from the mid- to late and very late luteal phase were analyzed with time-matched intervals in SEP. Comparing RMA-normalized transcripts from the natural cycle with those from luteal rescue revealed 7677 transcripts changing in expression pattern >2 fold (one-way ANOVA, FDR correction; P<0.05) between the two groups. Clustering of samples revealed that the SEP samples possessed the most related transcript expression profiles. Regressed CL (days 18-19, around menses) were the most unlike all other CL. The most affected KEGG pathway was Steroid Biosynthesis, and most significantly absent pathways following SEP treatment includes groups of genes whose products promote cell-death. By further comparing the genome-wide changes in luteal gene expression during rescue in SEP, with those in CL during luteolysis in the natural menstrual cycle, it is possible to identify key regulatory pathways promoting fertility. Simulated early pregnancy (SEP) treatment was begun on day 9 as Duffy and Stouffer (1997) by treatment of females with recombinant human chorionic gonadotropin (hCG; NovarelM-bM-^DM-", Ferring Pharmaceuticals Inc. Parsippany, NJ, USA) in increasing dosages (15, 30,45,90,180,360,720,1440, and 2880 IU) twice daily by intramuscular injection. CL were collected by laparotomy on days 10, 12, 15, and 18, representing 1, 3, 6 and 9 days of hCG treatment (n=4 CL/day). Additionally, luteal day 10 untreated CL were collected to serve as baseline controls for SEP CL. All CL were dissected away from luteal tissue, sectioned, and snap-frozen in liquid nitrogen and stored at -80M-BM-0C until RNA and protein isolation by TRIzolM-BM-. extraction (Invitrogen, Carlsbad, CA, USA) according to manufacturerM-bM-^@M-^Ys protocols.

Dataset Information

Acquisition of luteolytic capacity is accompanied by changes in luteal apoptosis and immune mechanisms

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets